Ongoing clinical trials are recruiting patients with metastatic, advanced, or relapsed/refractory cancers to evaluate the importance of blocking the FGF2/FGFR signaling in progressive and poor outcome cancer patients (Table 6). Here, FGF2 is linked to cancer.